Firms
Theme

UTZ

Utz Brands, Inc. · NYSE

News

15 latest

GlobeNewswire Inc.

$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD

Class action law firm Monteverde & Associates PC is investigating four major merger and acquisition transactions to determine if shareholders are receiving fair deal terms. The investigations involve Utz Brands' sale to Intersnack Group, Safety Insurance Group's sale to Mapfre affiliate, Passage Bio's merger with Remix Therapeutics, and Finward Bancorp's sale to First Financial Bancorp.

Zacks Investment Research

All You Need to Know About Utz Brands (UTZ) Rating Upgrade to Buy

Utz Brands received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company is positioned in the top 20% of Zacks-covered stocks for estimate revisions, suggesting potential near-term stock price appreciation. Analysts have raised consensus estimates by 2.4% over the past three months, with the company expected to earn $0.80 per share for fiscal year 2026.

Mentions UTZ

Zacks Investment Research

Boston Beer Q3 Earnings Beat on Margin Gains, Revenues Miss

Boston Beer (SAM) reported Q3 adjusted EPS of $4.37, beating consensus estimates, but revenues fell 3.2% to $520.1 million. Despite shipment volume declines of 4.9%, the company expanded gross margins through pricing actions and improved brewery efficiencies. SAM raised its 2026 adjusted EPS guidance to $9-$10.50 while expecting continued mid-single-digit volume declines.

Zacks Investment Research

Can Conagra Brands Sustain Its Foodservice Profit Momentum?

Conagra Brands' Foodservice segment delivered solid Q1 results with organic sales growth of 3.3% (fifth consecutive quarter), operating profit up 11.4%, and adjusted operating margin expansion of 83 basis points. Productivity gains successfully offset inflationary pressures, though approximately 150 basis points of volume growth came from accelerated customer orders. The stock trades at a forward P/E of 9.2, below industry and sector averages, but has underperformed the market over the past month.

Zacks Investment Research

Will Monster Beverage's Innovation & Global Expansion Aid Growth?

Monster Beverage (MNST) maintains a strong position in the global energy drink market, driven by brand investments, product innovation, and geographic expansion. U.S. Ultra sales surged 19% year-over-year while Juice Monster grew 26%, demonstrating innovation-led growth.

Zacks Investment Research

Constellation Brands Q2 Earnings Top Estimates on Beer and Wine Growth

Constellation Brands (STZ) reported Q2 fiscal 2027 earnings of $3.74 per share, beating consensus estimates, with net sales rising 6% to $2.63 billion. Beer sales grew 5% and wine/spirits jumped 17%, though operating margins contracted 160 basis points.

Zacks Investment Research

Can Sysco's Technology Push Drive Greater Efficiency and Savings?

Sysco Corporation is implementing a broad technology and AI transformation initiative targeting $100 million in net cost savings for fiscal 2027, with a $160 million run-rate from identified projects. The program leverages AI, routing software, and forecasting tools to improve margins, delivery efficiency, and working capital. Savings are expected to begin late in Q1 fiscal 2027 and accelerate in the second half of the year.

Zacks Investment Research

United Natural Foods' Lean Rollout Reaches 44 DCs: What's Next?

United Natural Foods (UNFI) has completed the initial deployment of Lean daily management across 44 distribution centers by the end of fiscal 2026. The initiative has yielded measurable improvements in key operational metrics: fill rates improved 2 points, on-time delivery advanced 5 points, and throughput rose 12 points year-over-year in Q4 fiscal 2026. The company plans to advance to Lean 2.0 to deepen adoption and further improve service and productivity metrics.

Zacks Investment Research

Can Hormel Foods Tackle Input Costs With Pricing and Efficiency?

Hormel Foods (HRL) is managing elevated input costs through pricing actions, supply chain improvements, and efficiency gains. While lower pork commodity prices began benefiting in Q3, the company still faces headwinds from higher beef, freight, logistics, and fuel costs. Management expects greater benefits from lower pork costs in future quarters as it implements multiple levers to protect profitability.

Zacks Investment Research

LW Q1 Earnings Beat Estimates on Higher North America Volume

Lamb Weston (LW) reported solid first-quarter fiscal 2027 results, beating consensus estimates on both sales and earnings. The company raised its fiscal 2027 guidance for sales, adjusted EBITDA, and earnings following stronger-than-expected performance. North America segment showed robust growth with seven consecutive quarters of volume gains, though international operations faced headwinds from weak European performance.

Zacks Investment Research

Can Darling Ingredients' Portfolio Reset Drive Long-Term Growth?

Darling Ingredients (DAR) completed the sale of its CTH-branded sausage casings business to SARIA as part of its portfolio optimization and debt reduction strategy. The company reduced net debt by $223 million in Q2 and is targeting year-end leverage below 2.0X. DAR's Food Ingredients segment showed strong performance with sales up 5.8% and adjusted EBITDA rising 55.1%, driven by improved collagen demand.

Zacks Investment Research

Can Medifast's Better Client Retention Support Revenue Stabilization?

Medifast (MED) reported Q2 2026 revenues of $76.4 million, down 27.6% year-over-year due to a 48.7% decline in active earning coaches to 11,700. However, the company showed positive signs with revenue per active coach increasing 41% to $6,529 for a third consecutive quarter, improved client retention, and strong referral program performance. Management expects Q3 revenues of $60-$80 million with continued coach productivity improvements.

Zacks Investment Research

Conagra Brands (CAG) Surpasses Q1 Earnings and Revenue Estimates

Conagra Brands reported Q3 earnings of $0.41 per share, beating consensus estimates of $0.31 by 32.26%, with revenues of $2.6 billion slightly exceeding expectations. However, the stock has underperformed the market by 18.4% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Food - Miscellaneous industry ranks in the bottom 18% of sectors.

Zacks Investment Research

Hormel Foods Pricing Strategy: Can It Balance Value and Profitability?

Hormel Foods executed two pricing rounds that contributed to a 1% decline in total dollar consumption in Q3, while adjusted operating margin improved 60 basis points to 9% and adjusted EPS rose 6% to 37 cents. The company is adapting its portfolio, messaging, pack formats and pricing to address consumers' growing emphasis on value. HRL carries a Zacks Rank #3 (Hold) with a forward P/E of 12.99.

Zacks Investment Research

Can Hershey's Innovation & Brand Investments Strengthen Demand?

The Hershey Company is ramping up demand creation efforts in the second half of 2026 by increasing brand investment by 30% year-over-year and launching 30% more innovation items, including new Hershey's Creme Filled Bars and Reese's Pieces with Cookie. The company is also strengthening seasonal programs and core-item availability to engage consumers amid selective spending patterns.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $UTZ · 0 threads

Sign in to post on $UTZ

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev